Esperion Therapeutics (NASDAQ:ESPR) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report released on Friday,Benzinga reports. They currently have a $5.00 target price on the biopharmaceutical company’s stock. ESPR has been the topic of several other reports. The Goldman Sachs Group cut their price objective on […]
Needham & Company LLC reiterated their buy rating on shares of Esperion Therapeutics (NASDAQ:ESPR – Free Report) in a research report released on Friday,Benzinga reports. They currently have a $5.00 target price on the biopharmaceutical company’s stock. ESPR has been the topic of several other reports. The Goldman Sachs Group cut their price objective on […]
